Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 491

Sort by

Sort Order Select

Journal Articles

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Evangelos Terpos, Ioannis P. Trougakos, Maria Gavriatopoulou, Ioannis Papassotiriou, Aimilia D. Sklirou, Ioannis Ntanasis-Stathopoulos, Eleni-Dimitra Papanagnou, Despina Fotiou, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2021) 137 (26): 3674–3676.

https://doi.org/10.1182/blood.2021011904

Published: 2021

Journal Articles

Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis

Mounica Vallurupalli, Nancy Berliner

Blood (2019) 134 (21): 1783–1786.

https://doi.org/10.1182/blood.2019002289

Published: 2019

Journal Articles

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults

Martha Hernandez-Illas, Tong Lin, Andres Rey, Jack Jenkins, Reddy Chandula, Mi Rim Choi, MD

Blood (2019) 134 (Supplement_1): 3817.

https://doi.org/10.1182/blood-2019-123695

Published: 2019

Journal Articles

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Jumpei Teramachi, Kazuaki Miyagawa, DDS, PhD, Delgado-Calle Jesus, PhD, Jolene Windle, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4336.

https://doi.org/10.1182/blood-2019-126959

Published: 2019

Journal Articles

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

Luke Maese, DO, Rachel E. Rau, MD, Elizabeth A. Raetz, MD, Tong Lin, Jin Zhu, Pil Kim, Reddy Chandula, Sherrie McClung, Julie Gray, Mi Rim Choi, MD, Mignon L. Loh, MD, Peter C. Adamson

Blood (2019) 134 (Supplement_1): 2586.

https://doi.org/10.1182/blood-2019-123710

Published: 2019

Journal Articles

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

Peter Müller, PhD, Bärbel Edelmann-Stephan, PhD, Fabian Richter, PhD, Klaus Pfizenmaier, PhD, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2966.

https://doi.org/10.1182/blood-2019-127997

Published: 2019

Journal Articles

One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B

Steven Pipe, MD, Adam Giermasz, MD PhD, Giancarlo Castaman, MD, Nigel S. Key, MBChB, FRCP, Susan U Lattimore, Frank Leebeek, MD PhD, Wolfgang Miesbach, MD PhD, Michael Recht, MD PhD, Esteban Gomez, MD, Alison Long, Robert Gut, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 3348.

https://doi.org/10.1182/blood-2019-128765

Published: 2019

Journal Articles

Seroprevalence of Pre-Existing Nabs Against AAV1, 2, 5, 6 and 8 in South African Hemophilia B Patient Population

Anna Majowicz, PhD, Nolukholo Ncete, MBBCH, Floris van Waes, MSc, Nikki Timmer, BSc, Sander J van Deventer, MD PhD, Johnny N Mahlangu, MBBCH, MMed, FCPath, Valerie Ferreira, PhD

Blood (2019) 134 (Supplement_1): 3353.

https://doi.org/10.1182/blood-2019-128217

Published: 2019

Journal Articles

Co-Prevalence of Pre-Existing Immunity to Different Serotypes of Adeno-Associated Virus (AAV) in Adults with Hemophilia

Kavitha Rajavel, Mila Ayash-Rashkovsky, Ying Tang, Bagirath Gangadharan, Maurus de la Rosa, Bruce Ewenstein

Blood (2019) 134 (Supplement_1): 3349.

https://doi.org/10.1182/blood-2019-123666

Published: 2019

Journal Articles

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Kenta Mukaihara, MD PhD, Mattia D'Agostino, MD, Cristina Panaroni, PhD, Keertik Fulzele, PhD, Tomoaki Mori, MD PhD, Ka Tat Siu, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2019) 134 (Supplement_1): 4382.

https://doi.org/10.1182/blood-2019-130462

Published: 2019

Journal Articles

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Tarun K. Garg, PhD, Cody Ashby, PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Frits van Rhee, MD PhD, Shmuel Yaccoby, PhD

Blood (2019) 134 (Supplement_1): 4412.

https://doi.org/10.1182/blood-2019-127382

Published: 2019

Journal Articles

Challenges in Management of Severe Hemophilia with Acute Hematologic Malignancies

Akshat Jain, MDMPH, Mary Meyer

Blood (2019) 134 (Supplement_1): 4940.

https://doi.org/10.1182/blood-2019-124895

Published: 2019

Journal Articles

Influence of Cyclophosphamide on L-Asparaginase-Induced Allergy in Animal Model

Ai Nogami-Hara, PhD, Akira Shimada, MD PhD, Mitsunobu Mio, PhD

Blood (2019) 134 (Supplement_1): 5119.

https://doi.org/10.1182/blood-2019-127179

Published: 2019

Journal Articles

Thrombin: A Driver or Attenuator of Bone Disease on Hemophilia?

Galen Goldscheitter, BS, BA, Robert Klein, MD, Jason A Taylor, MD PhD

Blood (2019) 134 (Supplement_1): 4916.

https://doi.org/10.1182/blood-2019-130698

Published: 2019

Journal Articles

Antibodies Against the Erythroferrone N-Terminal Domain Prevent Hepcidin Suppression and Ameliorate Murine Thalassemia

Blood (2019) 134 (Supplement_1): 964.

https://doi.org/10.1182/blood-2019-130246

Published: 2019

Journal Articles

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Blood (2019) 134 (Supplement_1): 911.

https://doi.org/10.1182/blood-2019-125007

Published: 2019

Journal Articles

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Christian Buske, MD PhD, Larry W Kwak, MD PhD, Wojciech Jurczak, MD PhD, Juan-Manuel Sancho, MD PhD, Edvard Zhavrid, MD PhD, Jin Seok Kim, MD PhD, Jose Angel Hernandez-Rivas, MD PhD, Aliaksandr Prokharau, MD PhD, Mariana Vasilica, MD PhD, Rajnish Nagarkar, MD PhD, Gayane Tumyan, DMSc, MD PhD, Won-Seog Kim, MD PhD, Michinori Ogura, MD PhD, Sang Joon Lee, PhD, Sung Hyun Kim, PhD, Keum Young Ahn, PhD

Blood (2019) 134 (Supplement_1): 1528.

https://doi.org/10.1182/blood-2019-126379

Published: 2019

Journal Articles

CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib

Shih-Shih Chen, PhD, Constantine S. Tam, MBBS (Hons), MD, Alan G. Ramsay, BSc,MSc,PhD, Priyadarshini Ravichandran, Natalia C. Couto-Francisco, Michael Ibrahim, Gerardo Ferrer, PhD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, He Zhou, Jacqueline C Barrientos, MD, Kanti R Rai, MD, Nicholas Chiorazzi, MD

Blood (2019) 134 (Supplement_1): 477.

https://doi.org/10.1182/blood-2019-127255

Published: 2019

Journal Articles

IL-33 Therapy Prevents Acute Lung Injury after Transplantation Via IL-9-Producing Type 2 Innate Lymphoid Cells Induction

Hua Jiang, PhD, Abdulraouf Ramadan, PhD, Becquet Laurine, MS, Tu Szu-Wei, Hong Liu, MS, Courtney Rowan, MD, Xiaowen Liu, PhD, Huanmei Wu, PhD, Jun Wan, PhD, Sophie Paczesny, MD PhD

Blood (2019) 134 (Supplement_1): 583.

https://doi.org/10.1182/blood-2019-123821

Published: 2019

Journal Articles

Therapeutic Doses of Recombinant FVIIa in Hemophilia Generates Thrombin in Platelet-Dependent and -Independent Manner

Shiva Keshava Gaddam Bala Krishna, PhD, Usha Pendurthi, PhD, L. Vijaya Mohan Rao, PhD

Blood (2019) 134 (Supplement_1): 1136.

https://doi.org/10.1182/blood-2019-128474

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B

Seroprevalence of Pre-Existing Nabs Against AAV1, 2, 5, 6 and 8 in South African Hemophilia B Patient Population

Co-Prevalence of Pre-Existing Immunity to Different Serotypes of Adeno-Associated Virus (AAV) in Adults with Hemophilia

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Challenges in Management of Severe Hemophilia with Acute Hematologic Malignancies

Influence of Cyclophosphamide on L-Asparaginase-Induced Allergy in Animal Model

Thrombin: A Driver or Attenuator of Bone Disease on Hemophilia?

Antibodies Against the Erythroferrone N-Terminal Domain Prevent Hepcidin Suppression and Ameliorate Murine Thalassemia

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib

IL-33 Therapy Prevents Acute Lung Injury after Transplantation Via IL-9-Producing Type 2 Innate Lymphoid Cells Induction

Therapeutic Doses of Recombinant FVIIa in Hemophilia Generates Thrombin in Platelet-Dependent and -Independent Manner

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only